drugset / Trial / NCT00099359

Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission

NCT00099359

RandomizedParallel-groupOpen-labelPrevention

Summary

Giving anti-HIV medications to babies born of HIV positive mothers right after birth can lower the babies' risk of contracting HIV. This study will assess the safety and efficacy of two different combinations of anti-HIV medications compared to a one drug standard regimen in preventing mother to baby transmission. The one drug standard treatment and two combinations to be studied are: 1) zidovudine, 2) zidovudine/nevirapine and 3) zidovudine/lamivudine/nelfinavir.

Timeline

Start
2004-02
Primary completion
2011-02
Completion
2011-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamivudine Other / unclassified 4 mg Oral
Subject Lamivudine Other / unclassified 6 mg Oral
Subject Nelfinavir Other / unclassified 100 mg Oral
Subject Nelfinavir Other / unclassified 150 mg Oral
Subject Nelfinavir Other / unclassified 200 mg Oral
Subject Nevirapine Small molecule 8 mg Oral
Subject Nevirapine Small molecule 12 mg Oral
Subject Zidovudine Small molecule 8 mg Oral
Subject Zidovudine Small molecule 12 mg Oral